EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Nexity, un des leader du marché de l’administration de biens, veut faire émerger des bonnes pratiques et transformer les métiers de services immobiliers aux particuliers. Nexity veut aussi répondre toujours mieux à ses clients propriétaires bailleurs avec des services qui correspondent vraiment à leurs besoins, en phase avec leur mode de vie de plus en plus connecté et mobile. D’où l’idée de leur proposer une nouvelle approche du mandat de gestion locative, 100% en ligne et à un coût particulièrement compétitif !
Beaucoup plus que la simple possibilité pour nos clients de pouvoir consulter en ligne les mouvements comptables correspondant à des mandats traditionnels, e-gérance leur permet, directement en ligne et en trois clics, de confier la responsabilité comptable, administrative et réglementaire à un mandataire expert. Tout en conservant la relation avec leur locataire et la gestion patrimoniale de leur bien.
To view the multimedia release go to:
http://www.multivu.com/players/fr/7747651-nexity-lance-e-gerance-gestion-locative/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
UBM Tech today introduced the new community-driven Insurance & Technology (insurancetech.com), an interactive platform for insurance technology professionals to connect with peers, editors and industry experts. The redesigned site provides the latest news, commentary and discussion on the most pressing issues that technology and business leaders face in the insurance marketplace. Complementing the brand’s award-winning editorial is perspective from more than 50 community contributors and subject matter experts involved in channel strategies, security, data management, compliance, policy administration, claims and underwriting.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7302151-ubm-tech-introduces-the-new-insurance-and-technology-interactive-platform/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Last December, nearly one-third of all car crash fatalities involved a drunk driver, according to the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA). Today, to help make our roads safer during the holiday season, the Television Bureau of Advertising (TVB) launched the 13th annual “Project Roadblock” initiative, in which local broadcast TV stations donate airtime to support NHTSA and the Ad Council’s “Buzzed Driving is Drunk Driving” PSA (public service advertising) campaign.
To help the campaign’s message reach those who could benefit most, the Ad Council is conducting a special push to TV stations in the 10 states that accounted for 53% of all alcohol-impaired driving fatalities in 2015: Texas, California, Florida, North Carolina, Georgia, Pennsylvania, Ohio, New York, Illinois, and South Carolina.
To view the multimedia release go to:
http://www.multivu.com/players/English/8003951-nhtsa-ad-council-tvb-anti-drunk-driving-psa/
The 1-year Full-Time MBA is the School’s flagship program with just about 100 MBA students. It is a challenging life time experience to learn the art of management and grow personally and professionally.
Full-Time MBA structure is organized around three cornerstones: Planning and Innovating, Controlling and Investing, Leading People and Processes. These core courses represent the competence requirements of a global manager.
To view the Multimedia News Release, go to http://www.multivu.com/players/uk/7674251-sda-bocconi-1-year-full-time-mba/
Today, HHS’ Administration for Children and Families (ACF), along with the National Responsible Fatherhood Clearinghouse, has launched a new series of public service advertisements (PSAs) recognizing the critical role fathers play in the lives of their children.
The public service campaign created by the non-profit Ad Council coincides with Tell a Joke Day and centers on the popularity and growing trend of telling “Dad” jokes. Through sharing dad jokes, the PSAs aim to communicate to fathers that the smallest moments spent with their children can make the biggest difference in their children’s lives. The ads direct fathers to Fatherhood.gov where users will find helpful tips, tools, information and jokes to help them get more involved with their kids.
To view the multimedia release go to:
https://www.multivu.com/players/English/8156551-ad-council-fatherhood-dad-jokes/
BioPharmX Corporation (OTCQB: BPMX) today announced the availability of Violet™ iodine, a new, once-daily pill for relief of premenstrual breast discomfort. The first-of-its-kind product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a condition known as fibrocystic breast condition (FBC), with the added benefit of promoting breast health for women of reproductive age.*
*These statements have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7378951-biopharmx-introducing-violet-iodine-premenstrual-breast-discomfort/
Nexity, un des leader du marché de l’administration de biens, veut faire émerger des bonnes pratiques et transformer les métiers de services immobiliers aux particuliers. Nexity veut aussi répondre toujours mieux à ses clients propriétaires bailleurs avec des services qui correspondent vraiment à leurs besoins, en phase avec leur mode de vie de plus en plus connecté et mobile. D’où l’idée de leur proposer une nouvelle approche du mandat de gestion locative, 100% en ligne et à un coût particulièrement compétitif !
Beaucoup plus que la simple possibilité pour nos clients de pouvoir consulter en ligne les mouvements comptables correspondant à des mandats traditionnels, e-gérance leur permet, directement en ligne et en trois clics, de confier la responsabilité comptable, administrative et réglementaire à un mandataire expert. Tout en conservant la relation avec leur locataire et la gestion patrimoniale de leur bien.
To view the multimedia release go to:
http://www.multivu.com/players/fr/7747651-nexity-lance-e-gerance-gestion-locative/
Nearly four out of five small business owners admit that they have not taken full advantage of national and community resources dedicated to helping small businesses develop and grow, according to a survey recently conducted by Fifth Third Bank.
In advance of Small Business Week May 1-7, Fifth Third Bank (NASDAQ: FITB) conducted a national survey of more than 500 small business owners to assess the landscape – and diagnose common pain points – of U.S. small business owners. According to the results, 81 percent of survey participants said they haven’t worked with local small business resources (e.g., chamber of commerce, SCORE, etc.). Forty-one percent were unsure if the United States Small Business Administration (SBA) had resources to help them. Roughly 38 percent of small business owners say they need help growing revenue and increasing profits.
To view the multimedia release go to:
http://www.multivu.com/players/English/7723852-fifth-third-bank-small-business/
